Ridova, Nevenka
Preferred name
Ridova, Nevenka
Official Name
Ridova, Nevenka
25 results
Now showing 1 - 10 of 25
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, CML-053 Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment(Elsevier BV, 2024-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience(Scientific Foundation SPIROSKI, 2021-09-11); ; ; <jats:p>Introduction: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the Severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with COVID-19 infection, including development of several autoimmune events that suggests that infection with SARS CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders. Aim: Review the hematological autoimmune phenomenon after infection with SARS-COV-2 in order to assist into the pathogenic mechanisms, clinical manifestations and treatment of this group of patients. Materials and methods: This is a retrospective study that includes 21 patients with autoimmune diseases like secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia( AIHA) and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology for a period of time from January 2020 to April 2021. Results: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic auto-immune presentations was 18,4 ± 10,3 days. The therapy of this conditions in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events. Conclusion: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patients. </jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience(Македонска академија на науките и уметностите, Одделение за медицински науки = Macedonian Academy of Sciences and Arts, Section of Medical Sciences/Walter de Gruyter GmbH, 2023-12-01); ; ; Stojanovska-Jakimovska, SimonaBackground: Treatment of Philadelphia chromosome negative myeloproliferative neoplasms (Ph - MPNs) requires individualized approach depending on multiple factors. Novel pegylated Interferon (IFN) formulations have become an attractive therapeutic option in young Ph- MPN patients associated with better patient compliance. Methods: In this retrospective observational study a total of 16 high-risk Ph- MPN patients treated off-label with ropeginterferon alfa-2b given twice monthly, were included. Median follow-up was 24 months. High-risk patients were defined using the IPSET score. Response to treatment was evaluated using ELN, IWG-MET EUMNET standardized criteria and occurrence of side effects was documented. Results: 11 patients were female (68.8%) and 5 male (31.2%); average age at diagnosis was 36 years (17-51); 12 patients (75%) had ET, one (6.2%) PV and three (18.8%) hypercellular phase of PMF. JAK2V617F mutation was detected in 10 patients (62.5%), CALR in three (18.8%), and three (18.7%) were triple-negative cases. In 7 patients (43.7%), ropeginterferon alfa-2b was used in first-line, and 9 (56.3%) were previously treated with HU and/or standard IFN. Among initially ropeginterferon alfa-2b treated patients, complete haematological response was observed in 4/7 (57.1%), partial in 2/7 (28.6%) and suboptimal in one (14.3%). Complete haematological response was observed in 8/9 (88.9%) among previously treated patients. Average time to blood count normalization was 8 weeks, at a dose ranging between 100mcg and 300mcg. Side effects were observed in one patient (6.2%). Conclusion: Our experience is in support of previous studies regarding ropeginterferon alfa-2b efficacy and safety profile in the treatment of young patients with Ph- MPNs. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, AUTOIMMUNE HEMOLITYC ANEMIA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: SINGLE CENTER EXPERIENCE(Macedonian Association of Anatomists, 2024); ; ; ; Popova-Labacevska, Marija - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Haploidentical Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Case Report First Experience(Scientific Foundation SPIROSKI, 2021-11-23); ; ; ; Popova-Labachevska, Marija<jats:p> BACKGROUND: Allogeneic stem cell transplantation (ASCT) is a potentially curative therapeutic approach in patients with intermediate and high-risk myelodysplastic syndrome (MDS). If a family sibling or unrelated donor is not available mismatched donors are viable option for young patients with no comorbidities. The aim of this case presentation was to evaluate our first experience with haploidentical transplantation for this indication. CASE PRESENTATION: We present a case of 50 years male patient with myelodysplastic syndrome (MDS) diagnosed at University Clinic for hematology, Skopje, North Macedonia. Patient was scored in IPSS -R as high risk patient. He was referred for HLA DNA typing of family siblings and since he didn’t have identical sibling and unrelated donor, he was referred to continue treatment with haploidentical stem cell transplantation. He received Flu Bu conditioning and PTCY, cyclosporine and MMF for GVHD prophylaxis. Peripheral blood stem cells (PBSC) from his mismatched brother were infused in the amount of CD34=5.8x106/kg. He experienced prolonged engraftment, severe infective bacterial infections and CMV reactivation with clinical manifestation of CMV colitis. He was successfully treated with antiviral drug and completely resolved. His bone marrow analysis showed complete remission and chimerism evaluation revealed high donor engraftment. Patient is now +34 months post transplant in complete remission. CONCLUSION: The use of a mismatched donor increases the risk of NRM, but there is also evidence to suggest that an haploidentical donor is a valid choice, as general outcome appears to be at least similar to MUD.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Poster: MM-326: Visceral Leishmaniasis Mimicking Multiple Myeloma(Elsevier BV, 2021-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment(Elsevier BV, 2024-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Analysis of Prognostic Factors As Predictors of Treatment Free Survival in Patients with Chronic Lymphocytic Leukemia-Single Centre Experience(2021-08); ; ; ; Krstevska-Balkanov, SvetlanaIntroduction: Chronic lymphocytic leukemia (CLL) is a heterogeneous clonal lymphoproliferative disease originating from activated B lymphocytes that have experienced antigen. The clinical course is very heterogeneous. Some patients never look for treatment, as opposed to others who live and die with an aggressive illness. This clinical heterogeneity is likely a reflection of molecular and cellular heterogeneity, on the basis of which patients with CLL can be divided into subgroups with different clinical-biological characteristics. Aim of the study: Evaluation of prognostic factors in terms of treatment free survival, prognosis and adequate therapeutic approach in patients with CLL. Material and methods: The study is set as retrospective, it includes 300 patients with CLL diagnosed and treated at the University Clinic of Hematology in the period of 10 years (January 2009 - January 2019). The study was performed at the University Clinic for Hematology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia. We evaluate several prognostic factors in terms of treatment free survival. All results were processed with the statistical program SPSS18 software program. Results: The multivariate Cox Proportional model of Treatment free survival of CLL patients confirmed ECOG, Rai Stage, and spleen size that influence on treatment free survival.. Concusion: In our study, multivariate analysis of treatment free survival and overall survival showed ECOG performance status 0,1 and 2 as a factor influencing both overall survival and treatment free survival - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Екстракорпорална фотофереза во третман на gvhd по алогена трансплантација на матични хематопоетски клетки(2023-06); ; ; Екстракорпоралната фотофереза (ЕКФ) претставува третман базиран на леукоцитна сепарација. Според последните препораки ЕКФ е индицирана како второ линиска терапија за хронична форма на болест на граф тот против домаќинот (Graft versus Host disease GvHD) кај пациентите кај кои е реализирана алогена транс плантација на хематопоетски матични клетки (ТХМК). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: SINGLE CENTER EXPERIENCE(Faculty of Medicine, UKIM, Skopje, 2023); ; ; ; Popova Labacevska, MarijaMonoclonal antibodies (mAbs) targeting CD20 molecule on B lymphocyte are of great importance in the treatment of B-cell malignancies. In recent years a great effort has been put in developing novel mAbs that can provide greater efficacy than the well-known rituximab. A second class of mAbs obinutuzumab has been presented as a more powerful tool in the treatment of this group of patients. In this retrospective study 70 patients with symptomatic CLL were included. CLL patients were diagnosed and treated at the University Clinic for Hematology between January 2018 and January 2022. All patients were evaluated for traditional clinical and laboratory prognostic factors and newer prognostic factors including IGHV mutation status and CLL prognostic and predictive genetic abnormalities. Most of the patients treated with obinutuzumab had Binet B stage (56%). Mutational status of the immunoglobulin variable region heavy chain (IGHV) in most of CLLpatients treated with obinutuzumab was unmated IGHV gene. The most frequently encountered adverse events were tumor lysis syndrome and leukopenia. The analysis of the initial results of the application of obinutuzumab-based therapy allows us to conclude that this therapeutical modality is not associated with severe adverseevents that would limit the administration of therapy.
- «
- 1 (current)
- 2
- 3
- »